# Tina Cascone

Source: https://onco.cc/people/tina-cascone/  
OnCo record `tina-cascone` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led CheckMate 77T, one of the perioperative immunotherapy trials that changed how operable lung cancer is treated.

## Summary

Tina Cascone was principal investigator of CheckMate 77T, which showed neoadjuvant nivolumab plus chemotherapy followed by adjuvant nivolumab improves event-free survival in resectable NSCLC, and led the NEOSTAR window trials that defined pathological response endpoints. Her laboratory studies the immune correlates of response to neoadjuvant therapy.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lung; neoadjuvant; immunotherapy
- Role: Associate Professor of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center
- Specialisms: Neoadjuvant immunotherapy; Perioperative NSCLC therapy; Translational immunology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Cascone%20T%5BAuthor%5D%20neoadjuvant%20nivolumab

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- trials: [CheckMate 816](https://onco.cc/trials/checkmate-816/), [KEYNOTE-671](https://onco.cc/trials/keynote-671/)
- key papers: [CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery](https://onco.cc/key-papers/paper-checkmate-816-nejm-2022/)

---
JSON: https://onco.cc/api/v1/entities/tina-cascone.json